Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Quaker Partners
AddedFeb 13, 2024
UpdatedJun 28, 2026
Quaker Partners

Quaker Partners

Operating

Quaker Partners Management is a US-based venture capital firm specializing in equity investments and management services in healthcare.

Location
Philadelphia, PA, US
Founded
2002
Firm
Compare
Portfolio
Employees

Investments

Kaarta
Kaarta

Total Raised

$6.5M

Rounds

3

Series A$6.5MMarch 2019
Tela Bio
Tela Bio
Public

Total Raised

$230.4M

Rounds

12

Series Unknown$25MOctober 2017
Rapid Micro Biosystems
Rapid Micro Biosystems
Public

Total Raised

$377.4M

Rounds

12

Series C$25MApril 2015
Series Unknown$6MApril 2014
Series B$32.6MJune 2013
Series A$18.6MAugust 2009
Neuronetics
Neuronetics
Public

Total Raised

$373.4M

Rounds

13

Series F$34.3MApril 2015
Series E$30MMay 2011
Series D$30MOctober 2009
Tarsa Therapeutics
Tarsa Therapeutics
Acquired

Total Raised

$124.3M

Rounds

9

Series B$7MMay 2014
Series B$28MMarch 2012
Series A$24MJanuary 2010
NovaSom
NovaSom

Total Raised

$114.6M

Rounds

10

Series D$35MJune 2011
Series F$20MOctober 2009
Corridor Pharmaceuticals
Corridor Pharmaceuticals
Public

Total Raised

$27.6M

Rounds

4

Series A$13MJune 2010
Series A$10.8MOctober 2009
Seed$2.3MOctober 2008
Helomics
Helomics

Total Raised

$211.5M

Rounds

11

Series D$33MJune 2010
Series Unknown$43MNovember 2008
BioLeap
BioLeap

Total Raised

$5M

Rounds

1

Series A$5MJanuary 2010
Asensus Surgical
Asensus Surgical
Public

Total Raised

$454.6M

Rounds

18

Post Ipo Equity$55MOctober 2009
Biolex Therapeutics
Biolex Therapeutics
Public

Total Raised

$196.7M

Rounds

9

Series D$60MOctober 2008
Diasome Pharmaceuticals
Diasome Pharmaceuticals
Public

Total Raised

$92M

Rounds

7

Series B$8.4MApril 2008
Tranzyme
Tranzyme
Acquired

Total Raised

$20M

Rounds

2

Series Unknown$20MNovember 2007
Optherion
Optherion

Total Raised

$42M

Rounds

2

Series A$37MOctober 2007